Drug General Information
Drug ID
D0T6TW
Former ID
DCL000825
Drug Name
GSK642444
Drug Type
Small molecular drug
Indication Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47] Phase 3 [537130]
Company
Theravance; GlaxoSmithKline
Structure
Download
2D MOL

3D MOL

Formula
C9H19N2OS+
Canonical SMILES
CCC(C)C(C(=O)N1CCSC1)[NH3+]
InChI
1S/C9H18N2OS/c1-3-7(2)8(10)9(12)11-4-5-13-6-11/h7-8H,3-6,10H2,1-2H3/p+1/t7-,8-/m0/s1
InChIKey
WCRLBFHWFPELKW-YUMQZZPRSA-O
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Beta-2 adrenergic receptor Target Info Agonist [532150], [532651], [537130]
KEGG Pathway Calcium signaling pathway
cGMP-PKG signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Endocytosis
Adrenergic signaling in cardiomyocytes
Salivary secretion
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Beta2 adrenergic receptor signaling pathway
Pathway Interaction Database Arf6 trafficking events
Arf6 signaling events
Reactome Adrenoceptors
G alpha (s) signalling events
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
GPCRs, Class A Rhodopsin-like
Vitamin D Receptor Pathway
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 537130Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
Ref 532150Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. PulmPharmacol Ther. 2013 Apr;26(2):256-64.
Ref 5326512013 FDA drug approvals. Nat Rev Drug Discov. 2014 Feb;13(2):85-9.
Ref 537130Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.